Dalvance Approval History
- FDA approved: Yes (First approved May 23rd, 2014)
- Brand name: Dalvance
- Generic name: dalbavancin
- Dosage form: Injection
- Company: Allergan plc
- Treatment for: Skin and Structure Infection
Dalvance (dalbavancin) is a second generation lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Development History and FDA Approval Process for Dalvance
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.